Delaying transplantation after total body irradiation is a simple and effective way to reduce acute graft-versus-host disease mortality after major H2 incompatible transplantation

Transplantation

Volumn 64, Issue 2, 1997, Pages 297-302

  Xun, Chang Q ^a,b   Tsuchida, Masanori ^a,c   Thompson, John S ^a,b  

^a UNIVERSITY OF KENTUCKY   (United States)

^b LEXINGTON VA MEDICAL CENTER   (United States)

^c NIIGATA UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

INTERLEUKIN 1BETA; INTERLEUKIN 6; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 2; TUMOR NECROSIS FACTOR ALPHA;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BONE MARROW TRANSPLANTATION; CHIMERA; FLOW CYTOMETRY; GRAFT SURVIVAL; GRAFT VERSUS HOST REACTION; HEMATOPOIESIS; MORTALITY; MOUSE; NONHUMAN; PRIORITY JOURNAL; SCID MOUSE; SPLEEN CELL; SURVIVAL RATE; WHOLE BODY RADIATION;

ANIMALS; BONE MARROW TRANSPLANTATION; GRAFT VS HOST DISEASE; H-2 ANTIGENS; INTERFERON TYPE II; INTERLEUKIN-1; INTERLEUKIN-6; MICE; MICE, INBRED BALB C; MICE, INBRED C57BL; SPLEEN; TIME FACTORS; TRANSPLANTATION CONDITIONING; TUMOR NECROSIS FACTOR-ALPHA; WHOLE-BODY IRRADIATION;

EID: 0030750397     PISSN: 00411337     EISSN: None     Source Type: Journal    
DOI: 10.1097/00007890-199707270-00021     Document Type: Article

References (20)

1. Antin JH, Ferrara JLM. Cytokine dysregulation and acute graft versus host disease. Blood 1992; 80: 2964.
2. Xun CQ, Thompson JS, Jennings CD, Brown SA, Widmer MB. Effect of total body irradiation, busulfan-cyclophosphamide or cyclophosphamide conditioning on inflammatory cytokine release and development of acute and chronic graft versus host disease in H-2 incompatible transplanted SCID mice. Blood 1994; 83: 2360.
3. Clift RA, Buckner CD, Appelbaum FR, et al. Allogeneic marrow transplantation in patients with acute myeloid leukemia in first remission: a randomized trial of two irradiation regimens. Blood 1990; 76: 1867
4. Holler E, Kolb HJ, Mittermuller J, et al. Modulation of acute graft-versus-host-disease after allogeneic bone marrow transplantation by tumor necrosis factor alpha (TNF alpha) release in the course of pre-transplant conditioning: role of conditioning regimens and prophylactic application of a monoclonal antibody neutralizing human TNF alpha (MAK 195F). Blood 1995; 86: 890.
5. Schwaighofer H, Kernan NA, O'rally RJ, et al. Serum levels of cytokines and secondary messages after T-cell-depleted and non- T-depleted bone marrow transplantation: influence of conditioning and hematopoietic reconstruction. Transplantation 1996; 62: 947.
6. Wang JH, Redmond HP, Wastson RW, Bouchier-Hayes D. Role of lipopolysaccharide and tumor necrosis factor alpha in induction of hepatocyte necrosis. Am J Physiol 1995; 269: G297.
7. Gabbianelli M, Boccole G, Cianetti L, Russo G, Testa U, Peschle C. HLA expression in hematopoietic development. Class I and II antigens are induced in the definitive erythroid lineage and differentially modulated by fetal liver cytokines. J Immunol 1990; 144: 3354.
8. Lehnert S, Rybka WB. Amplification of the graft-versus-host reaction by cyclophosphamide: dependence on timing of drug administration. Bone Marrow Transplant 1994; 13: 473.
9. Tsuchida M, Brown SA, Seehafer D, Tan J, Thompson JS. In vivo xenogeneic murine model: response and immunosuppressive effect of anti-T cell antibody on human skin rejection. Clin Transpl (in press).
10. Kishimoto T. The biology of interleukin-6. Blood 1989; 74: 1.
11. Kossodo S, Grau GE, Daneva T, et al. Tumor necrosis factor alpha is involved in mouse growth and lymphoid tissue development. J Exp Med 1992; 176: 1259.
12. Huss R, Deeg HJ, Gooley T, et al. Effect of mixed chimerism on graft-versus-host disease, disease recurrence and survival after HLA-identical marrow transplantation for aplastic anemia or chronic myelogenous leukemia. Bone Marrow Transplant 1996; 18: 767.
13. Sullivan KM, Weiden PL, Storb R, et al (The Seattle bone marrow transplant team). Influence of acute and chronic GVHD on relapse and survival after BMT from HLA-identical siblings as treatment of acute and chronic leukemia. Blood 1989; 73: 1720.
14. Xun CQ, Thompson JS, Jennings CD, Brown SA. The effect of human IL-2 activated natural killer and T cells on graft-versus- host disease and graft-versus-leukemia in SCID mice bearing human leukemic cells. Transplantation 1995; 60: 821.
15. Horowitz MM, Gale RP, Sondel PM, et al. Graft-versus-leukemia reaction after bone marrow transplantation. Blood 1990; 75: 555.
16. Nestel FP, Price KS, Seemayer TA, Lapp WS. Macrophage priming and lipopolysaccharide-triggered release of tumor necrosis factor alpha during graft-vs-host disease. J Exp Med 1992; 175: 405.
17. Collart MA, Belin D, Vassallli JD, Kossodo S, Vassalli P. Gamma Interferon enhanced macrophage transcription of the tumor necrosis factor/cachectin, interleukin 1 and urokinase genes which are controlled by short-live repressors. J Exp Med 1986; 164: 2113.
18. Neta R, Oppenheim JJ, Schrieber RD, Chizzonite R, Ledney GD, MacVittie TJ. Role of cytokines (IL-1, tumor necrosis factor and transforming growth factor B) in natural and lipopolysaccharide enhanced radioresistance. J Exp Med 1991; 173: 1177.
19. Ziegler-Heitbrock HW, Wedel A, Schraut W, et al. Tolerance to lipopolysaccharide involves of P50 homodimers. J Biol Chem 1994; 269: 1700.
20. Klimpel GR, Annable CR, Cleveland MG, Jerrells TR, Patterson JC. Immunosuppression and lymphoid hypoplasia associated with chronic graft versus host disease is dependent upon IFN gamma production. J Immunol 1990; 144: 84.